P aediatric Inflammatory Multisystem Syndrome Temporally related to SARS-CoV-2 (PIMS-TS), auch bekannt als MIS-C
Im Rahmen der zweiten Welle von COVID-19 sind in der Schweiz bei Kindern und Jugendlichen vermehrt Fälle von PIMS-TS aufgetreten (geschätzt ca. 50 Fälle). Über erste Fälle haben wir bereits im
Frühjahr 2020 berichtet.
Nun hat ein multidisziplinäres Expertenteam unter Leitung der IG neonatale und pädiatrische Intensivmedizin (IGNPI) der Schweizerischen Gesellschaft für Intensivmedizin (SGI) nationale Empfehlungen für die Diagnostik und Therapie des PIMS-TS erarbeitet und am 30.12.2020 publiziert.
pädiatrie schweiz, im Expertenteam durch mehrere Mitglieder vertreten, unterstützt diese neuen
Wichtig ist das frühzeitige Erkennen eines möglichen PIMS-TS.
Die Verdachtsdiagnose in der Grundversorgung sollte gestellt werden bei:
Fieber und schlechtem Allgemeinzustand über mehrere, i.d.R. ≥ 3 Tage UND stark erhöhtem CRP (100 – >300 mg/l) UND Klinischer Symptomatik mit a. Zeichen eines Kawasaki-Syndroms ODER b. Abdominalsymptomen (Bauchschmerzen, peritoneale Reizung, Diarrhoe) ODER c. Zeichen eines Kreislaufschock (wie bei Sepsis oder Toxic Shock Syndrom)
SARS-CoV-2 PCR bzw. Schnelltests sind mehrheitlich negativ, die Antikörper hingegen fast immer positiv. Meist liegt eine 2-6 Wochen zurückliegende, häufig asymptomatische Infektion vor.
Empfohlenes Vorgehen in der Grundversorgung: Bei Erfüllung der oben genannten Kriterien empfehlen wir die notfallmässige Zuweisung in eine Kinderklinik. Die virologischen Befunde sind nicht abzuwarten. Eine multidisziplinäre Betreuung ist für das optimale Management nötig. Medienmitteilung
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 1
Version 1.0, date 30.12.2020
Best Practice Recommendations for the Diagnosis and Management of Children with Paediatric
Inflammatory Multisystem Syndrome Temporally Associated with SARS -CoV -2 (PIMS -TS ;
M ultisystem Inflammatory Syndrome in Children , MIS -C) in Switzerland
the Swiss Society of Intensive Care (SGI)
the Swiss Interest Group for Pediatric and Neonatal Intensive Care (IGPNI)
the Pediatric Infectious Diseases Group Switzerland (PIGS)
the Swiss Society of Pediatrics (SGP)
Luregn J Schlapbach 1,2, MD, PhD, FCICM, Maya C Andre 3,4, MD, PhD, Serge Grazioli 5, MD, Nina
Schöbi , MD 6,7, Nicole Ritz 8, MD, Christoph Aebi 6, MD, Philipp Agyeman 6, MD, Manuela Albisetti 9,
Douggl GN Bailey 10, Christoph Berger 11, MD, Géraldine Blanchard Rohner 12, MD, DPhil, Michael
Hofer 12,13, MD, Arnauld G L’Huill ier12, MD, Mark Marston 3, MScN, Patrick M Meyer -Sauteur 11, MD,
PhD Jana Pachlopnik Schmid 14, MD, PhD, Mari e-Hel ene Perez 15, MD, Bjarte Rogdo 10, MD, Johannes
Trück 11,14, MD, D Phil , Andreas Woerner 16, MD, Petra Zimmerman 17,18, MD, PhD, Peter C
Rimensberger 5 MD, for the PIMS -TS working group of the Interest Group for Pediatric and Neonatal
Intensive Care (IGPNI) of the Swiss Society of Intensive Care and the Pediatric Infectious Diseases
Group Switzerland (PIGS)
1 Pediatric and Neonatal Intensive Care Unit, and Children`s Research Center, University Children’s
Hospital Zurich, Zurich, Switzer land
2 Child Health Research Centre, The University of Queensland, and Paediatric Intensive Care Unit,
Queensland Children`s Hospital , Brisbane, Australia
3 University of Basel Children´s Hospital, Division of Respiratory and Critical Care Medicine, Basel,
4 University Children´s Hospital, Dep artment of Pediatric Hematology and Oncology, Eberhard Karls
University, Tuebingen, Germany
5 Division of Neonatal and Pediatric Intensive Care, Department of Child, Woman and, Adolescent
Medecine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
6 Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
7 Alder Hey Children’s Hospital, NHS Foundation Trust, Liverpool, United Kingdom
8 Department of Infectiology and Vaccinology , University Children’s Hospital Basel, Basel, Switz erl and
9 Department of Haematology, and Children`s Research Center, University Children’s Hospital Zurich,
Zurich , Switzerland
10 Department of Pediatric Intensive Care , Children’s Hospital St. Gallen, St. Gallen, Switzerland
11 Division of Infectious Diseases and Hospital Epidemiology , University Children’s Hospital Zurich,
12 Unit of Immunology and Vaccinology, Division of General Pediatrics, Department of Pediatrics,
Gynecology and Obstetrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
13 Pediatric Immuno -Rheumatology of Western Switzerland, Department Women -Mother -Child,
Lausanne University Hospital, Lausanne, and University Hospitals of Geneva, Geneva, Switzerland
14 Division of Immunology and Children`s Research Center, University Chi ldren’s Hospital Zurich,
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 2
15 Pediatric Intensive Care Unit , University Hospital Lausanne, Lausanne, Switzer 16 Department of
Rheumatology, University Children’s Hospital Basel, Basel, Switzerland
17 Faculty of Science and Medicine, University of Fribourg and Department of Paediatrics, Fribourg
Hospital, Fribourg, Switzerland
18 Infectious Diseases Research Group, Murdoch Children’s Research Institute, Parkville,
Corresponding author/contact :
Prof. Luregn Schlapbach, MD, PhD , FCICM
Head, Pediatric and Neonatal Intensive Care Unit
University Children’s Hospital Zurich – Eleonore Foundation
CH -8032 Zurich Switzerland
phone +41 44 266 71 11
Key words : child; COVID -19; Kawasaki disease; multisystem inflammatory syndrome; MIS -C; pediatric
multisystem inflammatory syndrome; PIMS; sepsis; septic shock
Conflict of interest statement: none declared.
Word count manuscript: 3494
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 3
Background: Following the spread of the coronavirus disease 2019 (COVID -19 ) pandemic a new
disease e ntity emerged , defined as Paediatric Inflammatory Multisystem Syndrome temporally
associated with COVID -19 (PIMS -TS), or Multisystem Inflammatory Syndrome in Children (MIS -C).
In the absence of trials, evidence for treatment remains scarce .
Purpose: To develop best practice recommendations for the diagnosis and treatment of children with
PIMS -TS in Switzerland . It is acknowledged that the field is changing rapidly, and regular revision s in
the coming months are pre -planned as evidence is increasing.
Methods : Consensus guidelines for best practice were established by a multidisciplinary group of Swiss
paediatric clinicians with expertise in intensive care, immunology/rheumatology, infectious diseases,
and haematology. Subsequent to literature review, four worki ng groups established draft
recommendations which were subsequently adapted in a modified Delphi process. Recommendations
had to reach > 80 % agreement for acceptance .
Results: The group achieved agreement on 24 recommendations, which specify diagnostic approaches
and interventions across anti -inflammatory, anti -infectious, and support therapies for children with
suspected PIMS -TS. A management algorithm was derived to guid e treatment depending on the
phenotype o f presentation, categorized into PIMS -TS with a) shoc k, b) Kawasaki -disease like and c)
undifferentiated inflammatory presentation.
Conclusion : Using available literature and guidelines from international health auth orities , the Swiss
PIMS -TS recommendations represent best practice guidelines based on currently available knowledge
to standardize treatment of children with suspected PIMS -TS in Switzerland . Given the absence of high –
grade evidence, regular updates of the recommendations will be warranted , and participation of patients
in trials should be encouraged .
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 4
Subsequent to the first wave of the coronavirus disease 2019 (COVID -19) pandemic 1, clusters of
children presenting with unusual multisystem inflammatory condition s emerged 2,3. The clinical
syndrome show ed some heterogeneity with patients presenting either akin to toxic shock, Kawasaki –
disease like or with undifferentiated inflammatory characteristics , in addition to evidence of current or
past COVID -19 infection in the majority of cases 4,5. Accordingly, this new disease entity has been called
Paediatric Inflammatory Multisystem Syndrome temporally associated with COV ID -19 (PIMS -TS) as
per the Royal College of Paediatrics and Child Health case definition ( RCPCH,
https://www.rcpch.ac.uk/resources/guidance -paediatric -multisystem -inflammatory -syndrome –
temporally -associated -covid -19 -pims ) and Multisystem Inflammatory Syndrome associated with
COVID -19 (MIS -C) as per the C enter for Disease Control (CDC, https://www.cdc.gov/mis -c/) and the
WHO ( World Health Organisation, https://www.who.int/publications/i/item/multisystem –
inflammatory -syndrome -in-children -and -adolescents -with -covid -19 ).
While a number of studies have attempted to explain the underlying biological and genetic mechanism s
of PIMS -TS, its pathophysiology and the observed variation in clinical presentation remains largely
unknown 6-8. It is currently assumed that a complex process involving SARS -CoV -2-specific antigen
presentation to au toreactive T cells, superantigen -like viral structures, cross -reactive SARS -CoV -2-
specific antibodies and unbalanced cytokine responses may initiate PIMS -TS in genetically predisposed
children 9-13. In other p aediatric hyperinflammatory syndromes, such as Kawasaki disease (KD) ,
macrophage activation syndrome (MAS) , and hemophagocytic lymphohistiocytosis ( HLH ), timely
initiation of anti -inflammatory therapy and immunosuppression can often reverse the hyper –
inflammatory s tate and prevent or mitigate organ damage. Therefore, therapeutic immune modulation
is widely used as a mainstay of PIMS -TS treatment with the aim to inhibit cytokine secretion and restore
immune homeostasis . In addition , PIMS -TS patients may also show signs of vasculitis , endothelial
damage , and thrombosis, hence antiplatelet and anticoagulation management in PIMS -TS represent
important additional considerations 14.
In order to standardize management in Switzerland, we aimed to develop best practice
recommendations for the diagnosis and treatment of children with PIMS -TS .
Subsequent to a call for Expressions of Interest, the Interest Group for P aediatric and Neonatal Intensive
Care (IGPNI) of the Swiss Society of Intensive Care Medicine (SSICM) and the P aediatric Infectious
Diseases Group Switzerland (PIGS) formed a working group on PIMS -TS. In total, 22 pane llists across
the fields of p aediatric intensive care, infectious diseases, immunology and rheumatology, hematology
and nursing composed the panel.
Four sub groups focus ed on the domains of i) disease criteria and diagnosis, ii) anti -inflammatory
therapies, iii) anti -infective therapies, and iv) additional support therapies including coagulation
management. Each sub group performed a focused literature review on publications since the description
of PIMS -TS in early 2020 until December 2020. In addition, we searched for available pathways ,
diagnostic and therapeutic recommendations from different international institutions 15-17. Over a period
of five weeks, weekly virtual meetings of the entire working group were held to develop and discuss
the recommendations in a modified Delphi process. Finally, vo ting was performed by the entire panel
for each recommendation using Survey Monkey . The threshold for recommendations was met if >80%
of panel lists voted for full agreement on an item .
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 5
Statement of uncertainty:
At present, professionals remain confronted with substantial uncertainties regarding clinical
phenotypes, long -term outcomes , and optimal management 18. In the absence of randomized trials,
evidence for best treatment is minimal for the diagnostic, anti -inflammatory, anti -infectious, and
supportive measures which have be en proposed 6,19 . Recommendations therefore base primarily on
expert opinion and similar recommendations in the United Kingdom. The field is rapidly changing with
reports being published on an almost weekly basis 20, hence revision and updates of the
recommendations will be required regularly.
1. In Switzerland, the following case definition should be used:
Adapted RCPCH – case definition 21,22
Patient aged <18 years of age. Persistent fever + inflammation (elevated CRP and neutrophils,
or lymphopaenia) + single or multi organ dysfunction (shock, cardiac, respiratory, renal,
gastrointestinal, neurological) + additional features (see Table 1 ). This may include children
fulfilling full or partial criteria for Kawasaki disease (KD).
Exclusion of any other probable cause, such as bacterial sepsis, staphylococcal/streptococcal
shock syndromes, and viral infections associated with myocarditis. Waiting f or these results
should not delay seeking expert advice.
Positive for current or recent SARS -CoV -2 infection by PCR, serology, or antigen test ; or
COVID -19 exposure within 4 weeks prior to the onset of symptoms. Waiting for these results
should not delay seeking expert advice.
2. If a child fulfils the diagnostic criteria for PIMS -TS we recommend classifying these patients
according to the presenting phenotype due to the implications for diagnostic workup and management:
Shock -like presentation : signs of shock as per the Goldstein 2005 definition of cardiovascular
failure 23 (Appendix )
Kawasaki disease -like presentation : complete or incomplete with cardiac involvement,
according to AHA 24
Undefined inflammatory presentation : persistent pyrexi a with signs of PIMS -TS but not
meeting shock criteria nor having cardiac involvement
Overall, PIMS -TS remains a rare condition and most children with SARS -CoV -2 infection will remain
asymptomatic or will exhibit only mild symptoms 4,25 . Predominant clinical features include persistent
fever and gastrointestinal symptoms, e.g. abdominal pain, vomiting or diarrhoea. Many patients may
exhibit additional clinical features ( Table 1 ). Cardiovascular impairment can be manifest at
presentation or develop during admission 26,27 . Some patients show rapid clinical deterioration often
characterized by a vasoplegic shock state requiring admission to intermediate or intensive care units
(IMC /PICU ).4,28
It is paramount to avoid anchoring bias given that PIMS -TS remains a rare condition 29, and in view of
the fact that many children suffering from other disease during the pandemic may have concomitant
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 6
microbiological evidence of SARS -CoV -2 exposure. Other, more common differential diagnoses need
to be considered, such as, but not restricted to:
- Invasive bacterial infection
- Toxic shock syndrome (TSS)
- Staph ylococcal Scalded Skin Syndro me (SSSS)
- Kawasaki disease (KD)
- Viral myocarditis/infection (EBV, CMV, adenovirus, enterovirus, HHV6)
- Serum sickness
- Acute appendicitis/acute surgical abdomen
- Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH)
- Malignant disease s, e.g. acute leukaemia
Although the clinical presentation of PIMS -TS patients shares similarities with KD and TSS 4,25 , patients
with PIMS -TS have been reported to be older than KD patients and by definition lack microbial
confirmation of a staphylococcal or streptococcal infection.
We recommend a staged diagnostic approach, starting with standard investigations for all children
where PIMS -TS is suspected (Table 2 ), followed by more in -depth diagnostic work -up in children with
evidence of severe disease, or those with diagnostic uncer tainty. Early involvement of a paediatric
multidisciplinary team (MDT) including intensive care, immunology, infectious diseases,
rheumatology, cardiology, haematology and other s (e.g. general surgery ) should be considered .
Diagnostic measures, including laboratory tests such as markers of inflammation and organ dysfunction,
and imaging modalities such as echocardiography should be repeated sequentially depending on the
presentation , disease severity , and evolution to guide escalation and de -escalation of therapy, and to
rule out other diagnoses.
3. Patients who have been clinically well on regular wards with evidence of normal or recovering
cardiac function, and who have been afebrile (<38 degrees ) for 48 hours should be considered for
discharge home after MDT review.
In general, we suggest perform ing a follow -up visit 1 to 2 weeks and 6 weeks after discharge which
should encompass a multidisciplinary consultation. In children where cardiac involvem ent was
diagnosed, consultation of cardiology is recommended before discharge to guide frequency of follow -
up echocardiographic assessment, as cardiac function may not have fully normalized by the time of
Anti -inflammatory therapies
4. Therapeutic immune -modulation in PIMS -TS patients requires a multi disciplinary approach.
Clinicians should re -evaluate the patient response and consider differential diagnoses at every step.
We recommend a MDT approach to guide initiation , escalation, and tapering of empiric
immunomodulatory therapy, particularly because available evidence for such treatment is currently only
based on observational reports . The panel recommends using a management algorithm ( Figure 1 ) to
guide the step -wise selection of the initial interventions. Dosing recommendations are provided in
Table 3 and were adapted from the Imperial College Healthcare NHS Trust PIMS -TS guideline (Prof.
Elizabeth Whittaker , personal communication).
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 7
5. In patients with Kawasaki disease -like PIMS -TS, immunomodulation and management should follow
established guidelines for Kawasaki disease.
6. In patients with PIMS -TS shock, we recommend us ing immunoglobulins (IVIG, 2 g/kg) as first line
7. In patients with PIMS -TS shock we recommend treatment with intravenous pulse high -dose
methylprednisolone (10mg/kg to max 30 mg/kg q24h for 1 -3 days, max. 1 g/day).
8. In non -shocked patients with PIMS -TS undefined inflammatory presentation clinicians sho uld
consider administration of immunoglobulins (IVIG, 2 g/kg).
9. In non -shocked patients with PIMS -TS (Kawasaki -like presentation or undefined inflammatory
presentation) clinicians should consider administration of prednisolone (2 mg/kg q24h, max. 60
10. In all patients with confirmed PIMS -TS treated with steroids, steroids should be tapered over a
period of 2 -6 weeks depending on the clinical course and considering the clinical and biochemical (such
as CRP, D -Dimer and ferritin levels) response.
For children with Kawasaki disease -like PIMS -TS, the panel recommends that established institutional
or international guidelines such as the 2020 American College of Rheumatology guidelines 30 on
Kawasaki disease -like PIMS -TS should be followed. In addition, both the European SHARE initiative 31
and the American Heart Association guidelines 24 provide guidance on KD .
We recommend, based on currently available reports and in line with other recommendations, to use
intravenous immunoglobulin (IVIG) as the first line treatment in PIMS -TS patients presenting with
shock , and to consider IVIG in PIM S-TS with undefined presentation . While IVIG should be usually
administered as a single dose of 2g/kg (max. 100g/dose) , clinicians should assess the cardiac and fluid
status, particularly in patients in shock, as in some patients a slower administration become necessary .
Whi le corticosteroids have often been used as adjuncts to IVIG 32, the specific indication, dosing, timing
or type of glucocorticoid s in PIMS -TS remains unknown. The panel considered that benefit versus harm
justify pulse high -dose steroids for a duration of 1 to 3 days in PIMS -TS patients with shock , with an
initial dose of 10mg/kg methylprednisolone (max 1g/day) . Increasing the methylprednisolone dose to
30mg/kg q24h may be considered . PIMS -TS patients treated with pulse corticosteroids should receive
gastric protection with proton -pump inhibitors.
Given potential side effects and the lack of data , we advise against the use of pulse steroids in PIMS -
TS patients without shock but suggest to consider a lower dose therapy given intravenously and ,
subsequently, orally. While the optimal duration of steroid therapy in PIMS -TS remains unknown, the
joint view of the panel is that decisions on steroid treatment duration should be guided by the clinical
response (resolution of signs and symptoms), as well as by laboratory evidence of decreasing
inflammation and imp roving organ function. A longer course of steroids of up to 6 weeks may
contribute to prevent rebound inflammation.
A proportion of patients may not respond to initial treatment, and deter iorat ion of the disease can be
life -threatening. Refractory PIMS -TS is characterized by persistent fever and/ or increase of
inflammatory markers, worsening organ function, or increase in need of vasoactive drugs (measured by
Vasoactive -Inotrope Score 33) within 24 to 48 hours after start of treatment. Consideration of disease
severity in particular in PICU patients, and assessing evidence of persistent or progressive (multi -)
organ dysfunction is paramount to guide treatment escalation. Again, MDT a ssessment is recommended
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 8
and needs to take differential diagnoses into account at every step before escalating treatment , and
should carefully evaluate risk -versus -benefit ratio of escalating immunomodulat ory therapies . For
example, PIMS -TS patients may develop secondary infection s and immuno -suppressive treatment
regimens may further impair the host defense against infection . The current list of biological drugs
includes IL -1R (i.e. anakinra) , and IL -6R (i.e. tocilizumab) and tumor necrosis factor (TNF)
(infliximab) blocking agents (Table 3). In addition , clinicians may discuss administration of a second
dose of IVIG, or pulse steroids.
11. In patients with PIMS -TS refractory to initial treatment with IVIG and steroids, and after exclusion
of alternative causes by the multidisciplinary team, we suggest consideration for anakinra. We
recommend starting at 2 -3 mg/kg q12 h s.c. (max. 100 mg/dose, total of 4 -6 mg/kg/day). In case of
clinical improvement, stopping of anakinra after 48 to 72 h ou rs should be considered in the
multidisciplinary team .
12. In patients with PIMS -TS where no clinical and biochemical improvement to anakinra treatment is
observed within 24 -48 hours, the multidisciplinary team should consider other targeted
immunomodulation therapy with either tocilizumab or infliximab.
13. Clin ical assessment and serial laboratory testing on measures of inflammation and organ
dysfunction should guide escalation and duration of immunomodulation therapy treatment.
Despite its limited licensed indication, anakinra is increasingly chosen for off -label use in PIMS -TS
patients 4,34 -36. Anakinra has been approved for subcutaneous administration, however continuo us
intravenous administration has been reported 37. Its short half -life (4 -6 hrs) ( Table 3 ), allows for repeated
re-assessment of the immun osuppressive regimen. We therefore suggest a short trial of IL -1R blockade
in PICU -hospitalized PIMS -TS patients that have not responded within a period of 24 to 36 hours
following administration of both IVIG and steroids. Anakinra dose increase in the absence of clinical
improvement may be considered in the MDT. We suggest stopping anakinra after 48 -72 hours without
taper ing in case of clinical improvement . There is no evidence to support r outine s erial cytokine level
assessment to guide cytokine -targeted therapy (CTT) .
Tocilizumab is an IL -6R blocking agent currently approved for the treatment of both systemic and
polyarticular juvenile idiopathic arthritis in children above 2 years of age. Tocilizumab has also been
used in children with PIMS -TS as IL -6 has been described to be one of the main drivers of the
inflammatory cytokine storm in this dise ase entity. However, safety concerns exist as significant side
effects have been described such as a reversible elevation of liver enzymes and an increased risk for
bacterial and fungal infections ( Table 3). Therefore, tocilizumab should be reserved for children with
life -threatening PIMS -TS in whom anakinra has failed to show a clear benefit within 48 hours. Given
the long half -life (150 hours ) tocilizumab is usually given as a single intravenous dose.
The TNF -alpha blocking agent infliximab , classically used in children with various autoimmune
inflammatory diseases has also been successfully used in children with KD. However, since infliximab
increase s the risk for secondary infections , and ba sed on its long half -life (around 8 days, Table 3 ),
infliximab should only be administered to patients with PIMS -TS who failed to respond to anakinra and
as a single intravenous dose.
Anti -infective therapies
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 9
14. Based on the absence of evidence of remdesivir treatment for children with COVID -19 and the
proposed post -infectious concept of PIMS -TS 38 we do not recommend the routine administration of
remdesivir in PIMS -TS patients.
15. Children with suspected PIMS -TS and signs of shock or other organ dysfunction should be treated
empirically with intravenous broad -spectrum antimicrobial therapy for bacterial sepsis.
16. In children with PIMS -TS receiving intravenous antimicrobial therapy, we recommend daily
assessment (e.g., clinical, laboratory assess ment) for de -escalation of antimicrobial therapy in
consultation with infectious diseases specialists. Stopping of antimicrobial therapy should be considered
depending on the clinical course, microbiological findings, and the presence of PIMS -TS diagnostic
criteria, including evidence of recent or current SARS -CoV -2 infection by serology or PCR.
Remdesivir , a nucleoside analogue prodrug , has been approved for the treatment of COVID -19 in adults
based on emerging evidence demonstrating the efficacy in shortening time to clinical recovery 39,40 ,
however recent experience 39,41 has not confirmed these findings . The safety and effectiveness of
remdesivir for treatment of COVID -19 in children has not yet been evaluated (studies are underway)
outside case report s42,43 . Hence the role of remdesivir in the management of PIMS -TS is uncertain ,
especially as PIMS -TS represents a post -infectious disorder rather than active SARS -CoV -2 infection.
For these reasons the panel agreed that remdesivir should not be routinely used in children with PIMS -
TS. However, PIMS -TS patients may be considered for the compassiona te use of remdesivir on a case -
by -case basis 25,44 . When remdesivir is used the FDA emergency use authorization instructions for the
use of remdesivir in children >3.5 kg should be followed
Children with PIMS -TS initially often pres ent with signs and symptoms that mimic those of septic
shock and toxic shock syndrome 29 and neither clinical findings (fever, rash, abdominal symptoms),
infection marker s (CRP), nor other laboratory measures of inflammation may allow reliable
discrimination 45,46 . Mortality in children with sepsis and septic shock increase s as time to effective
antimicrobial therapy increases 47,48 . All suspected PIMS -TS patients with clinical signs of sepsis should
therefore receive prompt empiric intravenous antibiotics within one hour of pres entation for those with
shock, and within up to three hours for those without shock 49. The choice of antibiotics should be based
on local guidelines and taking into account age, epidemiology, and pre -existing medical conditions.
Antibiotics should be stream -lined or stopped on the basis of the clinical course and microbiological
culture results in discussion with t he infectious diseases team .
17. All PIMS -TS patients with shoc k or other organ dysfunction must be transferred to a centre with
availability of specialized P aediatric Intensive Care Units, cardiology, infectious diseases, and
18. Haemodynamic, respiratory, and other organ support should follow established guidelines such as
the Surviving Sepsis Campaign.
19. Extracorporeal Membrane Oxygenation should be considered in PIMS -TS with cardiac, respiratory,
or cardiorespiratory failure refractory to conventional management as per established guidelines
such as the Surviving Sepsis Campaign.
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 10
Many PIMS -TS patients do not show evidence of active viral infection and may be less likely to be
infectious to healthcare workers. However, clinical staff should wear appropriate personal protective
equipment 25 as per institutional guidelines. Children should be t riaged, assessed and management in
line with recommendations for management of fever in infants <36 months, Surviving Sepsis
Campaign 47, and standard PALS resuscitation algorithms for critically ill children. As some children
progress rapidly and may develop haemodynamic compromise , close monitoring and early referral to a
tertiary centre for cardiac and PICU review is important.
20. In the absence of cont raindications, we recommend starting prophylactic i.v. unfractionated
heparin at a dose of 10 U/kg/h in PIMS -TS patients with shock. Conversion to low molecular weight
heparin (LMWH, such as enoxaparin at a dose of 0.5 mg/kg q12hrs) after the first days sh ould be
considered, depending on renal function.
21. In any other PIMS -TS patient requiring intensive care admission, we recommend prophylactic
heparin (at a dose of 10 U/kg/h) or low molecular weight heparin (LMWH, such as enoxaparin at a dose
of 0.5 mg/kg s.c. q12hrs) depending on renal function.
22. For PIMS -TS patients not requiring PICU care, individual risk factors for thrombotic
complications should be assessed to guide decisions on individualized anticoagulation therapy.
23. In patients with Kawasaki disease -like PIMS -TS, antiplatelet management should follow
established guidelines for Kawasaki disease.
24. In PIMS -TS patients not showing Kawasaki disease -like presentation , treatment with low dose
aspirin (5mg/kg daily) should be considered.
Given the increased risk of thromboembolic complication s during acute PIMS -TS 14,50 , the panel advised
to use prophylactic anticoagulation in patients of higher severity requiring PICU admission . Starting
with intravenous heparin before converting to LMWH (pending normal renal function) is suggested. In
non PICU patients, the overall ass essment of the individual risk profile should include w ell -established
risk factors such as a previous history of venous thromboembolism or a first -degree relative with venous
thromboembolism, the presence of a central line, post -pubertal age or estrogen therapy amongst other.
In addition, obesity may increase risk for thromboembolic events in patients with SARS -CoV -2
infection or PIMS -TS. At the same time, clinicians should weigh benefit of antiplatelet and
anticoagulation treatments against the i ndividual risk for clinically relevant bleeding .
Similar to classical KD patients, children with PIMS -TS irrespective of the phenotype may be at risk
for the development of coronary artery aneurysms . Hence it appears to be reasonable to consider low
dose aspirin (5mg/kg) in addition to prophylactic antic oagulation in all critically ill patients with PIMS -
Within months of the COVID -19 pandemic spread, many countries across the globe have reported
children presenting unwell with features of severe inflammation and multisystem disease 51,52 . Using
available literatu re and guidelines from international institutions , the Swiss PIMS -TS recommendations
represent best practice guidelines based on currently available knowledge to facilitate and standardize
treatment of children with suspected PIMS -TS in Switzerland.
A number of limitations need to be considered. First, while the expert group includes specialists from
the relevant disciplines, numbers of children with PIMS -TS during the first wave of COVID -19 in
Switzerland were low , limiting experience in managing the d isease 11,34 . However, the group assessed
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 11
institutional pathways from other health care systems and consulted world leading experts in the field
during the process. Second, the literature review performed was not systematic but focussed. Third, to
date there are no published results from randomized controlled trials in the field, and the evidence ba se
for optimal PIMS -TS management remains minimal. Finally, recommendations were issued in the
context of a well -resourced setting, where IVIG and biologicals are relatively easily available , and may
not be applicable to resource limited settings. In relat ion to applying these guidelines, c linicians should
be mindful of the risk of anchoring bias during the pandemic. Many children may test positive for
COVID -19, not necessarily implying causality . The CDC, WHO and RCPCH case definitions of PIMS -
TS bear a risk to over diagnose an assumedly rare syndrome in children who suffer from other common
infectious or inflammatory or conditions such as septic shock, or rare r conditions such as HLH.
In conclusion, i t is imperative that children with PIMS -TS are enrolled in prospective trials where
feasible 53-55, and that clinical data are collected and shared to improve our understanding of th e disease
and its best management. Given the absence of high -grade evidence 18, regular updates of the
recommendations will be required.
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 12
We thank Laura Chapuisat, Swiss Society of Intensive Care, for the administrative support during the
project and voting. We thank Prof. Mike Levin, and Prof. Elizabeth Whittaker, Imperial College
London, for their valuable advice.
LJS and PCR designed and coordinated the work, wrote the first draft, and take responsibility for the
content of the work. MCA, NS, SG, and NR led subgroups and wrote the first draft on their section. All
other authors participated in literature review, voting, writing, and have seen and approved the final
1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid -19. N Engl J Med. 2020.
2. Levin M. Childhood Multisystem Inflammatory Syndrome - A New Challenge in the
Pandemic. N Engl J Med. 2020;383(4):393 -395.
3. Rimensberger PC, Kneyber MCJ, Deep A, et al. Caring for Critically Ill Children With
Suspected or Proven Coronavirus Disease 2019 Infection: Recommendations by the Scientific
Sections' Collaborative of the European Society of Pediatric and Neonatal Intensive Care.
Pediatr Crit Care Med. 2020.
4. Whittaker E, B amford A, Kenny J, et al. Clinical Characteristics of 58 Children With a
Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS -CoV -2.
JAMA. 2020;324(3):259 -269.
5. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syn drome in U.S.
Children and Adolescents. New England Journal of Medicine. 2020;383(4):334 -346.
6. Carter MJ, Shankar -Hari M, Tibby SM. Paediatric Inflammatory Multisystem Syndrome
Temporally -Associated with SARS -CoV -2 Infection: An Overview. Intensive Care Med.
7. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: A
systematic review. EClinicalMedicine. 2020;26:100527.
8. Gruber CN, Patel RS, Trachtman R, et al. Mapping Systemic Inflammation and Antibody
Responses in Mu ltisystem Inflammatory Syndrome in Children (MIS -C). Cell.
9. Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with
multisystem inflammatory syndrome associated with SARS -CoV -2 infection. Nat Med.
2020 ;26(11):1701 -1707.
10. Lee PY, Day -Lewis M, Henderson LA, et al. Distinct clinical and immunological features of
SARS –CoV -2–induced multisystem inflammatory syndrome in children. Journal of Clinical
Investigation. 2020;130(11):5942 -5950.
11. Grazioli S, Ta vaglione F, Torriani G, et al. Immunological assessment of pediatric
multisystem inflammatory syndrome related to COVID -19. J Pediatric Infect Dis Soc. 2020.
12. Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem Inflammatory
Syndrome i n Children with COVID -19. Cell. 2020;183(4):968 -981.e967.
13. Rowley AH. Understanding SARS -CoV -2-related multisystem inflammatory syndrome in
children. Nature Reviews Immunology. 2020;20(8):453 -454.
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 13
14. Goldenberg NA, Sochet A, Albisetti M, et al. Consens us-based clinical recommendations and
research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID -
19 -related illness. J Thromb Haemost. 2020;18(11):3099 -3105.
15. Dove ML, Jaggi P, Kelleman M, et al. Multisystem Inflammatory Syndrome in Children:
Survey of Protocols for Early Hospital Evaluation and Management. J Pediatr. 2020.
16. Harwood R, Allin B, Jones CE, et al. A national consensus management pathway for
paediatric inflammatory multisystem syndrome temporally associate d with COVID -19
(PIMS -TS): results of a national Delphi process. The Lancet Child & Adolescent Health.
17. Jonat B, Gorelik M, Boneparth A, et al. Multisystem Inflammatory Syndrome in Children
Associated With Coronavirus Disease 2019 in a Children's Hospital in New York City:
Patient Characteristics and an Institutional Protocol for Evaluation, Management, and Follow -
Up. Pediatr Crit Care Med. 2020.
18. Davey Smith G, Blastland M, Munafò M. Covid -19’s known unknowns. BMJ. 2020:m3979.
19. Nijman RG, De Guchtenaere A, Koletzko B, et al. Pediatric Inflammatory Multisystem
Syndrome: Statement by the Pediatric Section of the European Society for Emergency
Medicine and European Academy of Pediatrics. Frontiers in pediatrics. 2020;8:490.
doi:10.3 389/fped.2020.00490. Accessed 2020.
20. Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome
temporally associated with SARS -CoV -2 mimicking Kawasaki disease (Kawa -COVID -19): a
multicentre cohort. Ann Rheum Dis. 2020;79(8): 999 -1006.
21. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with
COVID -19. RCPCH. htt ps://www.rcpch.ac.uk/sites/default/files/2020 -05/COVID -19 -
Paediatric -multisystem -%20inflammatory%20syndrome -20200501.pdf . Published 2020.
Updated 1st May 2020. Accessed 17th November 2020.
22. Multisystem Inflammatory Syndrome in Children (MIS -C) Interim G uidance. American
Academy of Pediatrics. https://services.aap.org/en/pages/ 2019 -novel -coronavirus -covid -19 -
infections/clinical -guidance/multisystem -inflammatory -syndrome -in-children -mis -c-interim -
guidance/ . Published 2020. Updated 1st September 2020. Accessed 17th November 2020.
23. Goldstein B, Giroir B, Randolph A. Internationa l pediatric sepsis consensus conference:
definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med.
24. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long -Term
Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the
American Heart Association. Circulation. 2017;135(17):e927 -e999.
25. Harwood R, Allin B, Jones CE, et al. A national consensus management pathway for
paediatric inflammatory multisystem syndrome tem porally associated with COVID -19
(PIMS -TS): results of a national Delphi process. Lancet Child Adolesc Health. 2020.
26. Alsaied T, Tremoulet AH, Burns JC, et al. Review of Cardiac Involvement in Multisystem
Inflammatory Syndrome in Children. Circulation. 2020.
27. Valverde I, Singh Y, Sanchez -de -Toledo J, et al. Acute Cardiovascular Manifestations in 286
Children with Multisystem Inflammatory Syndrome Associated with COVID -19 Infection in
Europe. Circulation. 2020.
28. White M, Tiesman B, Handforth J, Kenny J. Paediatric inflammatory multisystem syndrome
temporally associated with SARS -CoV -2 (PIMS -TS): the Evelina Experience. Arch Dis
Child. 2020;105(11):1025 -1027.
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 14
29. Weiss SL, Peters MJ, Agus MSD, et al. Perspective of the Surviving Sepsis Campaign on the
Management of Pediatric Sepsis in the Era of Coronavirus Disease 2019. Pediatr Crit Care
30. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical
Guidance for Multisystem Inf lammatory Syndrome in Children Associated With SARS -CoV -
2 and Hyperinflammation in Pediatric COVID -19: Version 1. Arthritis Rheumatol. 2020.
31. de Graeff N, Groot N, Ozen S, et al. European consensus -based recommendations for the
diagnosis and treatment o f Kawasaki disease - the SHARE initiative. Rheumatology (Oxford).
32. Belhadjer Z, Auriau J, Méot M, et al. Addition of Corticosteroids to Immunoglobulins Is
Associated With Recovery of Cardiac Function in Multi -Inflammatory Syndrome in Children.
Circulation. 2020;142(23):2282 -2284.
33. Gaies MG, Gurney JG, Yen AH, et al. Vasoactive -inotropic score as a predictor of morbidity
and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med.
34. Fouriki A, Fougere Y, De Camaret C, et al. Case report: Anakinra treatment in children with
Multisystem Inflammatory Syndrome following SARS -CoV -2 infection in Switzerland. Front
35. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Ma nson JJ. COVID -19: consider
cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033 -1034.
36. Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the
use of intravenous anakinra in haemophagocytic lymp hohistiocytosis or macrophage
activation syndrome. Lancet Rheumatol. 2020;2(6):e358 -e367.
37. Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally
effective concentrations in the central nervous system within a therapeutic time window:
results of a dose -ranging study. J Cereb Blood Flow Metab. 2011;31(2):439 -447.
38. Diorio C, Henrickson SE, Vella LA, et al. Multisystem inflammatory syndrome in children
and COVID -19 are distinct presentations of SARS -CoV -2. J Clin Invest. 2020;130(11):5967 -
39. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid -19 - Final
Report. N Engl J Med. 2020.
40. Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid -19: a clinical practice
guideline. Bmj. 20 20;370:m2924.
41. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID -19: a randomised,
double -blind, placebo -controlled, multicentre trial. Lancet. 2020;395(10236):1569 -1578.
42. Orf K, Rogosic S, Dexter D, et al. Remdesivir during induct ion chemotherapy for newly
diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS -CoV -2
infection. Br J Haematol. 2020;190(5):e274 -e276.
43. Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals
for ch ildren with COVID -19/SARS -CoV -2. J Pediatric Infect Dis Soc. 2020.
44. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for
Coronavirus Disease 2019 (COVID -19): A Review. JAMA. 2020;323(18):1824 -1836.
45. Schlapbach LJ. Paediatric sepsis. Curr Opin Infect Dis. 2019;32(5):497 -504.
46. Schlapbach LJ, Kissoon N. Defining Pediatric Sepsis. JAMA Pediatr. 2018;172(4):312 -314.
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 15
47. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines
for the managemen t of septic shock and sepsis -associated organ dysfunction in children.
Intensive Care Med. 2020;46(Suppl 1):10 -67.
48. Evans IVR, Phillips GS, Alpern ER, et al. Association Between the New York Sepsis Care
Mandate and In -Hospital Mortality for Pediatric Se psis. JAMA. 2018;320(4):358 -367.
49. Weiss SL, Peters MJ, Alhazzani W, et al. Executive summary: surviving sepsis campaign
international guidelines for the management of septic shock and sepsis -associated organ
dysfunction in children. Intensive Care Med. 2020;46(Suppl 1):1 -9.
50. Diorio C, McNerney KO, Lambert M, et al. Evidence of thrombotic microangiopathy in
children with SARS -CoV -2 across the spectrum of clinical presentations. Blood Adv.
51. Antúnez -Montes OY, Escamilla MI, Figue roa -Uribe AF, et al. COVID -19 and Multisystem
Inflammatory Syndrome in Latin American Children: A Multinational Study. Pediatr Infect
Dis J. 2021;40(1):e1 -e6.
52. García -Salido A, De Carlos Vicente JC, Belda Hofheinz S, et al. Severe manifestations of
SARS -CoV -2 in children and adolescents: from COVID -19 pneumonia to multisystem
inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Critical
53. Garcia -Prats AJ, Salazar -Austin N, Conway JH, et al. COVID -19 pharmacologic treatments
for children: research priorities and approach to pediatric studies. Clin Infect Dis. 2020.
54. Goldman RD, Staubli G, Cotanda CP, et al. Factors associated with parents ' willingness to
enroll their children in trials for COVID -19 vaccination. Hum Vaccin Immunother. 2020:1 -5.
55. Campbell JI, Ocwieja KE, Nakamura MM. A Call for Pediatric COVID -19 Clinical Trials.
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 16
Figure 1: PIMS -TS Diagnostic and therapeutic algorithm.
PIM S-TS Diagnostic and Treatm ent Pathw ay
Evaluation for possible PIMS-TS
Triage, Assessment and Management for evidence of sepsis/inflammation
Consider DD for PIMS-TS (case definition & table 1 & checklist)
SignsofSHOCK (ref. Goldstein 2005, appendix)
•Resuscitate as per ABC approach
•Give broad spectrum antibiotics
•IVIG 2g/kg (max 100g) single dose
•Methylprednisolone pulse 10-30mg/kg/day
IV (max 1g) for 1-3 days then 2mg/kg/day
(max 60mg) * with slow wean
(unfractionated heparin 10 IU/kg/h IV)
•Consider low-dose aspirin 5mg/kg/day (max
100mg) but hold if plt< 80 G/L
Multidisciplinary evaluation and consider:
•Anakinra start 2-3mg/kg/dose q12h s.c.(max 100mg/dose),
increase by 1mg/kg/dose if unresponsive
•If deterioration or no clinical improvement consider other
biologicals (Tocilizumab, Infliximab)* or second dose IVIG 2g/kg
No clinical improvement 24-36 hours after first IVIG and
methylprednisolone pulse dose (alternative causes excluded)
Treat per local Kawasaki
•IVIG 2g/kg (max 100g)
2mg/kg/day (max 60mg) *
in children with high risk for
IVIG resistance or >5 y old
Multidisciplinary evaluation and
•IVIG 2g/kg (max 100g) single dose
•Prednisolone 2mg/kg/day (max
60mg)* with slow wean
•Low-dose aspirin (5mg/kg/day,
max 100mg) but hold if plt< 80
MDT: immunology, infectious diseases, respiratory medicine, rheumatology, cardiology, intensive care, general paediatrics, haematology(surgery, radiology,
neurology); consider expert opinion from another center
*Refer to the treatment Table 3for more details
No clinical improvement with persistent fever
and/or inflammation (alternative causes excluded)
Multidisciplinary evaluation and consider:
•Methylprednisolone 10-30mg/kg/day (max 1g) for
1-3 days, then 2mg/kg/day * with slow wean
•Second dose IVIG 2g/kg
•Biologicals (Anakinra, Tocilizumab, Infliximab) *
PICU with MDT support
1st & 2nd line investigations
1st line investigations (table 2)
Laboratory results consistent with PIMS-TS
2nd line investigations (table 2)
Features of cardiac involvement w/o shock(abnormal echo,
arrhythmias or ECG changes, elevation of cardiac enzymes,
cardiomegaly on CXR)
=> MDT and re-consider admission to IMC/PICU
“PIMS-TS undefined inflammatory
Alternative diagnosis ?
Viral infection (EBV, CMV, Adenovirus,..)
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 17
Table 1. List of diagnostic criteria for PIMS -TS . Patients must be below 18 years and meet
at least one criterion for each group, including i) presence of fever, ii) organ involvement, iii)
laboratory evidence of inflammation, iv) microbiological ly proven or putative COVID -19
contact, and v) exclusion of other causes.
Required Fever O
Organ systems Single or multi -organ involvement
Gastrointestinal Abdominal pain, diarrhoea, vomiting
Abnormal liver function tests
Colitis, ileitis, ascites
Cardiovascular Hypotension, shock, oliguria
Myocardial dysfunction, pericardial effusion
Coronary artery dilatation
Respiratory Cough, sore throat
Patchy infiltrates, pleural effusion
Dermatologic Conjunctivitis, periorbital swelling/redness
Mucus membrane changes
Swollen hands and feet
Neurologic Headache, confusion, irritability, reduced level of
Abnormal laboratory findings indicating inflammation (any combination)
Elevated CRP / fibrinogen / D-Dimers / ferritin,
hypoalbuminaemia, lymphopaenia, neutrophilia
Cardiac markers Elevated Troponin / NT -pro -BNP O
COVID -19 contact Either confirmed or putative O
Confirmed Positive for current or recent SARS -CoV -2
infection by PCR, serology, or antigen test
Putative COVID -19 exposure within the 4 weeks prior to
the onset of symptoms
No alternative plausible diagnosis (microbial or inflammatory) O
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 18
Table 2. Recommendations for diagnostic work -up in children evaluated for PIMS -TS.
Note: where possible, PIMS -TS patients should be enrolled in observational or interventional
studies, which may include additional diagnostics.
Initial investigations in case
of suspected PIMS -TS
(according to disease severity)
Full blood count (FBC)
C-reactive protein (CRP)
Blood gas , lactate , glucose
Urea, creatinine, electrolytes (U&E)
Liver function tests (LFTs)
Coagul ation: INR, aPTT, Fibrinogen
Blood cultures (always before starting antibiotics)
Urine microscopy and culture
NPA: respiratory panel, SARS -CoV -2 PCR
Lumbar puncture if clinically indicated
Second line investigations :
(in addition to initial bloods)
Desirable measures which
should NOT delay seeking
expert opinion or treatment
Erythrocyte sedimentation rate (ESR)
NT -pro -BNP
Store serum and EDTA blood (before administration of IVIG)
EBV/CMV/Adeno -/Enterovirus blood PCR
SARS -CoV -2 serology
12 -lead ECG and echokardiography
Abdominal ultrasound (if gastrointestinal symptoms)
IL -10, IL -6, sCD25*
* consider full HLH screen if suggestive features present (e.g.
sple nomegaly, fibrinogen normal or low; ferritin >2000):
Perforin -, SAP – and XIAP -expression, NK cell degranulation and
consider HLH -directed therapy (MDT)
Follow up investigations: Unstable patient (deteriorating or in PICU):
12 -24 hourly: FBC, CRP, U&E, LFT s, coagulation, f erritin;
parameters that need to be repeated guided by clinical progress
such as Troponin and NT -pro -BNP , e cho cardiography (in
consultation with cardiology)
Stable patient with ongoing pyrexia:
24 -48 hourly: FBC, CRP U&E, LFTs, ferritin
Echocardiography 48 hourly (in consultation with cardiology)
Child improving +/ – defervescence:
48 hourly bloods or pre -discharge bloods: FBC, CRP, U&E,
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 19
Echocardiography before discharge
*Children with evidence of cardiac involvement sho uld be discussed with a tertiary centre for
cardiology involvement and care in PICU should be considered.
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 20
Table 3. Anti -inflammatory therapies in patients with PIMS -TS. DISCLAIMER: Medication dosing and administration should be checked with the
local hospital pharmacists and considering recent evidence updates . W here possible, PIMS -TS patients should be enrolled in interventional
studies. Data were a cc essed from www.accessdata.fda.gov/ , www.ema.europa.eu/ , and the British Paediatric Allergy, Immunity, and Infection
Group ( Position Statement: Management of novel coronavirus (SARS -CoV -2) infection in paediatric patients in the UK and Ireland) and adapted
from the Imperial College Healthcare NHS Trust PIMS -TS guideline for external use . MDT, multidisciplinary team; IVIG, intravenous
Class Drug Route Dose Duration Comments and side effects
Blood products IVIG IV 2 g/kg (max 100g) Infusion over
Side effects: Aseptic meningitis, volume load, systemic inflammation,
haemolytic an aemia, neutropenia. Slower the rate or divide the dose over
two days if signs of volume overload or severe cardiac dysfunction
Corticosteroids Methylprednisolone IV
2 mg/kg daily (max 60 mg/day)
10-30 mg/kg daily for 1 -3 days
(max 1 g/day)
discuss in MDT
Side effects: Hyperglycaemia, hypertension, agitation
Prednisolone PO 1 mg/kg q12h or
2 mg/kg q24h
Up to 2 -6
Taper: over 2 -6 weeks
(recombinant interleukin -1 receptor
SC start at 2 -3 mg/kg q12 hours
Escalation/taper: MDT decision. IV administration possible under different
Side effects: neutropenia, leukopenia, thrombocytopenia, eosinophilia,
headache, abdominal pain, nausea/vomiting, diarrhea, hepatitis, increased
serum transaminases, hypersensitivity reactions, injection -site reactions, skin
interleukin -6 receptor
IV < 30kg: 12 mg/kg single dose
30kg: 8 mg/kg single dose
Escalation: If no clinical improvement after initial dose, may repeat dose 8 -
12 hours after the initial dose after MDT discussion .
Side effects: neutropenia, leukopenia, thrombocytopenia, anemia, pain,
headache, dizziness, insomnia, demyelinating disorders, ulcerations,
nausea, increased serum transaminases, liver impairment, increase in
serum lipids, pancreatitis, hypertension, hypothyroidism, hypersensitivity
reactions, Steven -Johnson -Syndrome, c onjunctivitis, nephrolithiasis,
injection -site reactions, rash
(chimeric tumour necrosis factor TNF
IV 5 mg/kg single dose Discuss in
Side effects: neutropenia, leukopenia/agranulocytosis, thrombocytopenia,
anemia, pain, headache, dizziness, insomnia, demyelinating disorders,
hypersensitivity reactions, injection -site reactions, skin rash
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: firstname.lastname@example.org, www.sgi -ssmi.ch 21
2005 International Pediatric Sepsis Definition Consensus Conference criteria for shock
(as per Goldstein, B., et al. 2005 "International pediatric sepsis consensus conference:
definitions for sepsis and organ dysfunction in pediatrics." Pediatr Crit Care Med 2005;
6(1): 2 -8; with corrigenda in Gebara , B. M. et al. "Values for systolic blood pressure."
Pediatr Crit Care Med 2005; 6(4): 500; author reply 500 -501 ).
Presence of the following despite appropriate intravenous fluid resuscitation:
blood pressure <5th centile for age or systolic blood pressure <2 SD below normal for
need for vasoactive drugs to maintain blood pressure in normal range
two of the following:
- unexplained metabolic acidosis (base deficit >5.0 mEq/L)
– arterial lactate >2 times upper limit of normal
– oliguria (urine output <0.5 ml/kg/h)
- capillary refill time >5 sec
– core to peripheral temperatu re gap >3° Celsius
HLH diagnostic criteria:
(as per Pachlopnik Schmid J, Volkmer B, Ehl S: “Classification, clinical manifestation and
diagnosis of HLH”. Abla O. and Janka G. (eds.): Histiocytic Disorders. Springer Verlag ,
Stuttgart 2018; page 173 – 187. ISBN (online): 978 -3-319 -59632 -7)
The diagnosis of HLH can be established if (A) and (B) are fulfilled
A. A molecular diagnosis consistent with HLH: disease -causing mutations in PRF1 , UNC13D ,
Munc18 -2, STX11 , RAB27A, LYST, SH2D1A , or BIRC4
B. Five out of the eight criteria listed below are fulfilled:
1. Fever ≥ 38.5 °C
2. Splenomegaly (palpable below costal margin or increased size by imaging)
3. Cytopenia (affecting ≥ 2 out of the 3 lineages):
Hemoglobin (<90 g/l; in newborns, <100 g/l)
Age Group Systolic Blood Pressure (mmHg)
0 days – 1 week <5 9
1 week to 1 months <79
1 months – 1 year <7R
1 – 5 years <74
S-12 years <8P
13 - <18 years <9M
Generalsekretariat SGI IMK Institut für Medizin und Kommunikation AG, Münsterberg 1, 4001 Basel Tel. 061 / 561 53 64, E-Mail: email@example.com, www.sgi -ssmi.ch 22
Neutrophilic granulocytes (<1.0 G/l)
Platelet count (<100 G/l)
4. Hemophagocytosis (in the bone marrow or CSF)
5. Hyperferritinemia ( ≥ 500 μg/l)
6. Hypertriglyceridemia (fasting level, ≥ 3.0 mmol/l) or hypofibrinogenemia ( ≤ 1.5 g/l)
7. Elevated soluble CD25 (=soluble IL2 receptor, sIL2R) ( ≥ 2400 U/ml)
8. Decreased NK -cell cytotoxicity